Abstract 10046: Catecholamine-Mediated Stress Cardiomyopathy Following Abrupt Tizanidine Withdrawal
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.10046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Zina Ibrahim und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Abrupt cessation of tizanidine, a centrally acting alpha-2 adrenergic agonist, may produce a rebound catecholaminergic state characterized by tachycardia, hypertension, and autonomic instability. Severe cardiac complications associated with tizanidine withdrawal are poorly described. We present a case of stress-induced cardiomyopathy following cessation of high-dose tizanidine with concomitant fluvoxamine use, a potent CYP1A2 inhibitor known to increase tizanidine exposure. Patient Information: A 24-year-old female with obsessive-compulsive disorder and peripheral neuropathy presented with palpitations and vomiting after discontinuing tizanidine. She had recently escalated her dose to 25 mg daily for worsening neuropathic pain while on fluvoxamine. Clinical Findings and Timeline: On arrival, the patient was tachycardic to 155 bpm, normotensive, and saturating 98% on room air. Initial laboratory evaluation was unremarkable, and she was admitted for suspected tizanidine withdrawal. On hospital day two, she developed pleuritic chest pain and acute hypoxic respiratory failure prompting transfer to the cardiac intensive care unit. Diagnostic Assessment & Reasoning: Labs were notable for high-sensitivity troponin of 1551 ng/L and NT-proBNP of 25823 pg. EKG showed sinus tachycardia. TTE demonstrated severe, global left ventricular systolic dysfunction with EF 20%, no left ventricular hypertrophy, normal right ventricular systolic function, and no valvular dysfunction. Given isolated LV involvement without evidence of focal wall motion abnormalities, stress-induced cardiomyopathy was suspected. Therapeutic Interventions: Treatment included alpha-agonist replacement and intensive hemodynamic support. The clinical course was complicated by refractory tachycardia, respiratory failure, and vasopressor-dependent hypotension. Following stabilization, low-dose tizanidine was reintroduced with clinical improvement. Follow-up, Outcomes, Adverse Events: Repeat TTE demonstrated rapid recovery of LVEF 50%, further supporting a diagnosis of reversible catecholamine-mediated stress cardiomyopathy. Cardiac MRI showed LVEF 42% without evidence of myocardial infarction, scar, or infiltrative disease. CT coronary angiography demonstrated no coronary artery disease. Genetic testing for hereditary cardiomyopathy is ongoing. The patient was discharged on tizanidine with an outpatient taper and guideline-directed medical therapy (metoprolol, losartan, spironolactone, and dapagliflozin).
Discussion
This case highlights tizanidine withdrawal as a potential trigger of catecholamine-mediated stress cardiomyopathy. Concomitant use of fluvoxamine likely increased tizanidine exposure through CYP1A2 inhibition. Clinicians should recognize the cardiovascular risks of severe tizanidine withdrawal.
Zitieren
APA
Ibrahim, Z., King, B., Schwennesen, H., & Narcisse, D. I. (2026). Abstract 10046: Catecholamine-Mediated Stress Cardiomyopathy Following Abrupt Tizanidine Withdrawal. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.10046
Vancouver
Ibrahim Z, King B, Schwennesen H, Narcisse DI. Abstract 10046: Catecholamine-Mediated Stress Cardiomyopathy Following Abrupt Tizanidine Withdrawal. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.10046
BibTeX
@article{Ibrahim2026,
author = {Ibrahim, Zina and King, Brandon and Schwennesen, Hannah and Narcisse, Dennis I},
title = {Abstract 10046: Catecholamine-Mediated Stress Cardiomyopathy Following Abrupt Tizanidine Withdrawal},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.10046}
}
EUVIMED